This content was funded by UCB Biopharma, SRL. This content is intended for EU healthcare professionals only.
Please refer to your local prescribing information for Certolizumab Pegol.
Click here to view the EU Summary of Product Characteristics.
Adverse event reporting information can be found at the bottom of this page.
Tune into this video to learn more about how CIMZIA® (certolizumab pegol) could impact quality of life in adult patients with moderate-to-severe plaque psoriasis.
EU-CZ-2500002
Date of preparation: April, 2025
| Adverse events should be reported. Healthcare professionals (HCPs) are asked to report any suspected adverse reactions to https://www.ucb.com/UCBCares.com |
